Effective peptide therapy requires patient education on self-injection, storage, monitoring, and side effect management. This reference provides comprehensive patient education materials for major peptide classes.
| Item | Description | Notes |
|---|
| Syringe | 1 mL or 0.5 mL insulin syringe | Match to dose volume |
| Needle | 29–32G, 3/8–5/16 inch | Ultra-fine preferred |
| Alcohol swab | 70% isopropyl alcohol | For site preparation |
| Sharps container | FDA-cleared container | For needle disposal |
| Gauze pads | 2×2 inch sterile | For post-injection pressure |
| Site | Absorption Rate | Recommended For |
|---|
| Abdomen (2 inches from navel) | Fastest | Most peptides |
| Outer upper arm | Moderate | Alternative site |
| Thigh (front/outer) | Slowest | Alternative site |
| Buttock | Variable | Not recommended |
Rotation: Rotate injection sites within each region, spacing at least 1 inch apart to prevent lipodystrophy.
- Wash hands thoroughly with soap and water.
- Prepare medication: Check expiration date, appearance (clear or slightly opalescent).
- Clean injection site with alcohol swab; allow to air dry (30 seconds).
- Pinch skin: Gently pinch a 1-inch fold of skin at the injection site.
- Insert needle: Insert at 90° angle (or 45° for thin patients) with a quick, dart-like motion.
- Inject medication: Push plunger slowly and steadily over 5–10 seconds.
- Withdraw needle: Release skin pinch, withdraw needle at same angle as insertion.
- Apply pressure: Use gauze; do not massage (may affect absorption).
- Dispose of needle: Immediately place in sharps container.
| Device | Manufacturer | Training Resources |
|---|
| Ozempic Pen | Novo Nordisk | Manufacturer video tutorial |
| Mounjaro Pen | Eli Lilly | Manufacturer video tutorial |
| Victoza Pen | Novo Nordisk | Manufacturer video tutorial |
| Trulicity Pen | Eli Lilly | Manufacturer video tutorial |
| Tresiba FlexTouch | Novo Nordisk | Manufacturer video tutorial |
Tip: Most manufacturers offer in-person or virtual injection training sessions through their websites or customer service lines.
| Peptide | Unopened | In-Use (Opened) | Temperature Range |
|---|
| Semaglutide (Ozempic) | Until expiration | 56 days | 2–8°C or 8–25°C |
| Semaglutide (Wegovy) | Until expiration | 28 days (refrigerated) | 2–8°C |
| Tirzepatide (Mounjaro) | Until expiration | 21 days | 2–8°C or 8–25°C |
| Liraglutide (Victoza) | Until expiration | 30 days | 2–8°C |
| Dulaglutide (Trulicity) | Until expiration | 14 days | 2–8°C or 25°C |
| Insulin glargine | Until expiration | 28 days (opened) | 2–8°C or 25°C |
| Insulin degludec | Until expiration | 56 days (opened) | 2–8°C or 25°C |
| Insulin lispro | Until expiration | 28 days (opened) | 2–8°C or 25°C |
- Refrigerate unopened medication: Store at 2–8°C (36–46°F).
- Do not freeze: If medication has been frozen, discard it.
- Protect from light: Keep in original carton until use.
- Room temperature storage: Most peptides can be stored at room temperature (2–25°C) for a limited time (see table).
- Do not return to refrigerator: Once at room temperature, do not re-refrigerate.
- Carry medication in a cool bag with ice packs for long trips.
- Keep medication in carry-on luggage (not checked baggage).
- Carry a copy of the prescription.
- For international travel, check import regulations.
| Parameter | Frequency | Target Range |
|---|
| Fasting glucose | Daily (if on insulin) | 80–130 mg/dL |
| Postprandial glucose | 2 hours after meals | <180 mg/dL |
| HbA1c | Every 3–6 months | <7.0% (individualized) |
| Continuous glucose monitoring | If available | Time in range >70% |
| Parameter | Frequency | Target |
|---|
| IGF-1 | Every 1–3 months | Age-matched normal range |
| Glucose | Every 1–3 months | Fasting <100 mg/dL |
| Prolactin | Baseline and 3 months (GHRP-6) | Normal range |
| Cortisol | Baseline and 3 months (GHRP-6) | Normal range |
| Parameter | Frequency | Notes |
|---|
| Weight | Weekly | Track trends |
| Blood pressure | Weekly | Hypertension screening |
| Injection site | Every injection | Check for lipodystrophy |
| Side effects | Ongoing | Report severe effects |
| Side Effect | Management Strategy |
|---|
| Nausea | Eat smaller meals; avoid fatty/spicy foods; take with food |
| Diarrhea | Stay hydrated; avoid caffeine; consider loperamide |
| Vomiting | Eat slowly; avoid large meals; take antiemetic |
| Constipation | Increase fiber, water; consider stool softener |
| Injection site reactions | Rotate sites; do not reuse needles |
| Decreased appetite | Eat nutrient-dense foods; small frequent meals |
Titration Tip: Most GI side effects occur during dose titration and resolve within 2–4 weeks. Start at the lowest dose and increase gradually.
| Side Effect | Management Strategy |
|---|
| Hypoglycemia | Follow “Rule of 15”: 15g fast-acting carbs, recheck in 15 min |
| Weight gain | Monitor portions; increase activity; consider dose optimization |
| Lipodystrophy | Rotate injection sites; do not reuse needles |
| Injection site pain | Use ultra-fine needles; ensure room temperature |
| Side Effect | Management Strategy |
|---|
| Injection site reactions | Rotate sites; do not reuse needles |
| Headache | Stay hydrated; consider acetaminophen |
| Flushing | Usually mild; resolve within 30 minutes |
| Joint pain | Monitor; report if persistent |
| Water retention | Monitor weight; report rapid weight gain |
| Peptide | Frequency | Best Time | Reminders |
|---|
| Semaglutide (Ozempic) | Once weekly | Any day, same time | Phone alarm |
| Tirzepatide (Mounjaro) | Once weekly | Any day, same time | Phone alarm |
| Liraglutide (Victoza) | Once daily | Any time | Phone alarm |
| Insulin degludec | Once daily | Any time (flexible) | Phone alarm |
| Insulin glargine | Once daily | Same time each day | Phone alarm |
- Set a consistent day/time for weekly injections.
- Use a medication tracker (app or calendar).
- Prepare injection materials in advance.
- Keep backup supplies (needles, alcohol swabs) in a travel kit.
- Plan for travel: Carry enough medication and supplies.
- Communicate with your care team: Report missed doses promptly.
- Refill prescriptions early: Allow 3–5 days before running out.
| Symptom | Action |
|---|
| Severe hypoglycemia (unconscious) | Call emergency services; administer glucagon |
| Persistent vomiting (>24 hours) | Contact prescriber; may need IV fluids |
| Severe injection site infection | Contact prescriber; may need antibiotics |
| Signs of pancreatitis (severe abdominal pain) | Seek emergency care |
| Allergic reaction (hives, swelling, difficulty breathing) | Call emergency services |
| Significant weight gain (fluid retention) | Contact prescriber |
Patient education is essential for safe and effective peptide therapy. Key components include proper injection technique, appropriate storage, regular monitoring, side effect management, and adherence strategies. Most peptide side effects are manageable with dose titration and lifestyle modifications. Patients should be empowered with knowledge about when to seek medical attention and how to optimize their therapy for best outcomes.
